Absolute Bioavailability
Absolute Bioavailability is a pharmacokinetic parameter defined as the fraction of an administered dose of a drug that reaches the systemic circulation unchanged after administration by a particular route, as determined by comparing its systemic exposure (e.g., area under the concentration–time curve) with that achieved after intravenous administration of the same dose.
144
Publications
7K
Citations
662
Authors
203
Institutions
Publications per year
2017–2026
7
144
Dose-Related Kinetics of Aspirin
Anders Kirstein Pedersen, Garret A. FitzGerald · New England Journal of Medicine · 1984 · 557 citations
The Absolute Bioavailability of Oral Melatonin
Rob L. DeMuro, Anne N. Nafziger, David E. Blask et al. · The Journal of Clinical Pharmacology · 2000 · 239 citations
1–5 of 144
662
3
h-index
3
h-index
3
h-index
3
h-index
Bristol-Myers Squibb (United States), United States
3 publications · 124 citations
3
h-index
1–5 of 662
203
Bristol-Myers Squibb (United States)
New York, United States
6 h-index
45 publications
1.4K citations
United States Food and Drug Administration
Silver Spring, United States
4 h-index
7 publications
440 citations
Janssen (United States)
Hopewell, United States
3 h-index
6 publications
188 citations
Pfizer (United States)
New York, United States
3 h-index
12 publications
240 citations

GlaxoSmithKline (United Kingdom)
London, United Kingdom
3 h-index
3 publications
71 citations
Bristol-Myers Squibb (Germany)
Munich, Germany
3 h-index
7 publications
160 citations
Heidelberg University
Heidelberg, Germany
3 h-index
15 publications
818 citations
Bayer (Germany)
Leverkusen, Germany
2 h-index
4 publications
95 citations
1–8 of 203
Repository · 20 publications · 649 citations
14
h-index
13 publications · 976 citations
13
h-index
9 publications · 306 citations
9
h-index
8 publications · 608 citations
8
h-index
CPDD · 5 publications · 136 citations
6
h-index
1–5